Cognitive Behavioral Tx for Insomnia Assists CA Survivors

This article originally appeared here.
Share this content:
Cognitive Behavioral Tx for Insomnia Assists CA Survivors
Cognitive Behavioral Tx for Insomnia Assists CA Survivors

THURSDAY, Dec. 4, 2014 (HealthDay News) -- For cancer survivors, cognitive behavioral therapy for insomnia (CBT-I) with and without armodafinil is associated with decreases in insomnia severity and improvements in sleep quality, according to a study published online Dec. 1 in the Journal of Clinical Oncology.

Joseph A. Roscoe, Ph.D., from the University of Rochester Medical Center in New York, and colleagues conducted a randomized trial involving 96 cancer survivors (mean age, 56 years) to assess insomnia treatment outcomes. The authors examined whether one or more of the seven-week intervention conditions (CBT-I, armodafinil, or both) produced greater clinical gains when compared with a placebo group.

The researchers observed significantly greater reductions in insomnia severity postintervention in both CBT-I plus armodafinil (P = 0.001) and CBT-I plus placebo (P = 0.010) groups, compared with placebo, after adjustment for baseline differences; the effect sizes were 1.31 and 1.02, respectively. Similar improvements in sleep quality were observed. Three months later, the gains on both measures persisted. There was no significant difference for CBT-I plus armodafinil or CBT-I plus placebo (P = 0.421), and no significant difference was seen for armodafinil alone versus placebo alone (P = 0.584).

"CBT-I results in significant and durable improvements in insomnia and sleep quality," the authors write.

The study was partially funded by Teva Pharmaceuticals, which provided study medication.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »